New approach to treat acute viral infections in children under 3 years of age: multicenter, double-blind, randomized, placebo-controlled trial of imidazolyl ethanamide pentandioic acid

Abstract

Acute respiratory viral infections (ARVIs), including influenza, are the most common human infections. Young children are particularly vulnerable to ARVIs due to the specificity of their immune system. Therefore, the search for new effective and safe drugs for children is one of the most important problems in pediatrics. Objective. To assess the efficacy and safety of Ingavirin® syrup 30 mg/5 mL for the treatment of ARVI in children aged 6 months to 3 years. Patients and methods. This study included 240 children aged 6 months to 2 years 11 months and 14 days who had the symptoms of ARVI/influenza upon enrollment. Children were randomly assigned to one of the two groups to receive Ingavirin® or placebo. The drug was taken orally once a day in accordance with the weight/dose table for 5 days. The maximum duration of follow-up was 14 days. Results. We found that Ingavirin® ensured more rapid symptom resolution and pathogen elimination than placebo. Key words: influenza, imidazolyl ethanamide pentandioic acid, Ingavirin®, acute respiratory viral infections, antiviral therapy